Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEN-DEC GITMO Study
2024-518792-54-00Phase 2Completed
- Sponsor
- GITMO
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and decitabine in acute myeloid leukemia (AML), sponsored by GITMO. Primary endpoint: Proportion of patients proceeding to allo-SCT in remission. Started Dec 2024; status: completed.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-518792-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518792-54-00.